CLOSE
Mario Tama/Getty Images
Mario Tama/Getty Images

To Get Women to Bike More, Build Better Bike Lanes

Mario Tama/Getty Images
Mario Tama/Getty Images

Biking is a great way to stay healthy and get around town without paying for gas, but not everyone bikes in equal numbers. There’s a gender gap in bike commuting, one that’s easily illustrated by bike-share numbers. Several years after its launch, the membership of New York’s Citi Bike program was less than a third female, and it isn’t a problem that’s unique to New York or bike-sharing in general.

A good way to get more women cycling, though, is to install more bike lanes, as researchers from the University of British Columbia and the University of Colorado concluded in a recent study in the Journal of Transport and Land Use. It sounds intuitive and, indeed, studies have shown that adding bike infrastructure leads to more people biking in general.

But it’s particularly important to talk about how to get women on bikes because the gender gap in cycling is so large in the U.S., even though the approximately equal shares of women and men biking in Europe tell us that riding a bike isn’t a uniquely male activity.

The latest study examined cycling demographics by neighborhood in Montreal and Vancouver, two cities that both have a diverse selection of bike infrastructure ranging from painted lanes to cycleways separated from the street. The researchers found that if a neighborhood had access to some kind of bike infrastructure within about half a mile (1 kilometer), that area saw four times as many people cycling as neighborhoods without bike lanes. But the difference between cycling on the road with cars and cycling in a dedicated lane of some sort had an even more significant impact for women specifically.

Though women make up half the commuters in Montreal and Vancouver, they were much less likely than men to ride bikes to and from work if there wasn’t any bike infrastructure. In some neighborhoods without infrastructure, only a tenth of the cycling commuters were women, while in one with better access to bike lanes, women made up almost half of the cyclists. When more bike commuters were hitting the road in a neighborhood, the percentage of men and women was about equal, perhaps because of the “safety in numbers” phenomenon.

Shaded maps of Montreal and Vancouver show the percentages of commuters bike.
The percentage of commuters in each neighborhood who get to work by bicycle, with darker colors indicating a greater share.
Teschke et al., Journal of Transport and Land Use, 2017

“To give women an equal opportunity to bike to work, municipalities need to build a great quality cycling network,” Kay Teschke, a professor of public health at the University of British Columbia and the study’s lead author, said in a Q&A with UBC’s news team.

The new study data, taken from 2011 Census results, may paint a slightly different picture than you might find in those cities now, six years later, when there might be new bike lanes or more bike commuters. Not to mention the fact that bike lanes aren’t necessarily spread evenly throughout a city, so other factors may be influencing this data, as the researchers admit. For instance, wealthier neighborhoods tend to have better bike infrastructure, which is why bike lanes have become a symbol of gentrification. But the results do track with previous research on the subject. A study in 2013 found that women cared more about cycling near bike paths or trails than men did, and several studies have found that women are more concerned about the safety issues associated with riding a bike than male riders.

Whether for men or women, though, the study makes it clear that cities could do a lot more to encourage cycling. People were more likely to bike if their neighborhood had an interconnected web of bike lanes, not just a few scattered paths. “The pattern of results suggested that the network formed by other bikeway types may have been more important than the specific bikeway characteristics,” the researchers write.

“Even though biking is faster and easier, more people walked to work than biked to work in both cities,” Teschke noted in her Q&A. She suggests that one reason could be that sidewalks are ubiquitous, but bicycle lanes are not—and whether men or women, people are apt to choose a mode of transport that makes them feel safe over one that’s a little more convenient but makes them think they’re about to get run over at any minute.

And while it might not seem that important to get women on bikes, cycling has major benefits that, ideally, the whole population should enjoy. Surveys find that people who cycle to work are happier than other types of commuters, and a 2016 study found that cyclists in the Netherlands outlive non-cyclists.

nextArticle.image_alt|e
iStock
arrow
Medicine
New Cancer-Fighting Nanobots Can Track Down Tumors and Cut Off Their Blood Supply
iStock
iStock

Scientists have developed a new way to cut off the blood flow to cancerous tumors, causing them to eventually shrivel up and die. As Business Insider reports, the new treatment uses a design inspired by origami to infiltrate crucial blood vessels while leaving the rest of the body unharmed.

A team of molecular chemists from Arizona State University and the Chinese Academy of Sciences describe their method in the journal Nature Biotechnology. First, they constructed robots that are 1000 times smaller than a human hair from strands of DNA. These tiny devices contain enzymes called thrombin that encourage blood clotting, and they're rolled up tightly enough to keep the substance contained.

Next, researchers injected the robots into the bloodstreams of mice and small pigs sick with different types of cancer. The DNA sought the tumor in the body while leaving healthy cells alone. The robot knew when it reached the tumor and responded by unfurling and releasing the thrombin into the blood vessel that fed it. A clot started to form, eventually blocking off the tumor's blood supply and causing the cancerous tissues to die.

The treatment has been tested on dozen of animals with breast, lung, skin, and ovarian cancers. In mice, the average life expectancy doubled, and in three of the skin cancer cases tumors regressed completely.

Researchers are optimistic about the therapy's effectiveness on cancers throughout the body. There's not much variation between the blood vessels that supply tumors, whether they're in an ovary in or a prostate. So if triggering a blood clot causes one type of tumor to waste away, the same method holds promise for other cancers.

But before the scientists think too far ahead, they'll need to test the treatments on human patients. Nanobots have been an appealing cancer-fighting option to researchers for years. If effective, the machines can target cancer at the microscopic level without causing harm to healthy cells. But if something goes wrong, the bots could end up attacking the wrong tissue and leave the patient worse off. Study co-author Hao Yan believes this latest method may be the one that gets it right. He said in a statement, "I think we are much closer to real, practical medical applications of the technology."

[h/t Business Insider]

nextArticle.image_alt|e
iStock
arrow
Medicine
New Peanut Allergy Patch Could Be Coming to Pharmacies This Year
iStock
iStock

About 6 million people in the U.S. and Europe have severe peanut allergies, including more than 2 million children. Now, French biotechnology company DBV Technologies SA has secured an FDA review for its peanut allergy patch, Bloomberg reports.

If approved, the company aims to start selling the Viaskin patch to children afflicted with peanut allergies in the second half of 2018. The FDA's decision comes in spite of the patch's disappointing study results last year, which found the product to be less effective than DBV hoped (though it did receive high marks for safety). The FDA has also granted Viaskin breakthrough-therapy and fast-track designations, which means a faster review process.

DBV's potentially life-saving product is a small disc that is placed on the arm or between the shoulder blades. It works like a vaccine, exposing the wearer's immune system to micro-doses of peanut protein to increase tolerance. It's intended to reduce the chances of having a severe allergic reaction to accidental exposure.

The patch might have competition: Aimmune Therapeutics Inc., which specializes in food allergy treatments, and the drug company Regeneron Pharmaceuticals Inc. are working together to develop a cure for peanut allergies.

[h/t Bloomberg]

SECTIONS

arrow
LIVE SMARTER
More from mental floss studios